b68594bb-fca3-4f05-a9fa-1e6e88eb4fc5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.200
- MYC_TARGETS_V1+0.180
- WNT_BETA_CATENIN_SIGNALING+0.180
- TGF_BETA_SIGNALING+0.140
- E2F_TARGETS+0.120
- SPERMATOGENESIS+0.120
- DNA_REPAIR+0.080
- KRAS_SIGNALING_DN+0.010
- UNFOLDED_PROTEIN_RESPONSE+0.010
- G2M_CHECKPOINT-0.010
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.520
- INTERFERON_GAMMA_RESPONSE-0.490
- INFLAMMATORY_RESPONSE-0.470
- IL6_JAK_STAT3_SIGNALING-0.430
- TNFA_SIGNALING_VIA_NFKB-0.420
- ALLOGRAFT_REJECTION-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- APICAL_JUNCTION-0.350
- PI3K_AKT_MTOR_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 50d87a6b-8e96-4964-9f23-53cc48c7d9ff | — | — | 0.918 |
| 2 | SRR17866817 | — | — | 0.898 |
| 3 | SRR1313141 | — | E | 0.897 |
| 4 | ERR2208946 | — | — | 0.895 |
| 5 | BS_1BWP5MCT | medulloblastoma | — | 0.888 |
| 6 | s_150324_3b | EPN | Posterior Fossa EPN | 0.884 |
| 7 | SAMN03290896 | — | — | 0.884 |
| 8 | TCGA-D6-6827-01A-11R-1915-07 | — | — | 0.879 |
| 9 | BS_QRDT19KS | medulloblastoma | — | 0.876 |
| 10 | BS_TE0GVDNG | medulloblastoma | — | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |